Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma

Patients with multiple myeloma (MM) inevitably relapse on initial treatment regimens, and novel combination therapies are needed. Ibrutinib is a first‐in‐class, once‐daily inhibitor of Bruton's tyrosine kinase, an enzyme implicated in growth and survival of MM cells. Preclinical data suggest su...

Descripción completa

Detalles Bibliográficos
Autores principales: Chari, Ajai, Cornell, Robert F., Gasparetto, Cristina, Karanes, Chatchada, Matous, Jeffrey V., Niesvizky, Ruben, Lunning, Matthew, Usmani, Saad Z., Anderson, Larry D., Chhabra, Saurabh, Girnius, Saulius, Shustik, Chaim, Stuart, Robert, Lee, Yihua, Salman, Zeena, Liu, Emily, Valent, Jason
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496325/
https://www.ncbi.nlm.nih.gov/pubmed/32053229
http://dx.doi.org/10.1002/hon.2723

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496325/
https://www.ncbi.nlm.nih.gov/pubmed/32053229
http://dx.doi.org/10.1002/hon.2723

Ejemplares similares